[International consensus conference on hepatitis C. Conclusions. Organized under the auspices of the European Association for the Study of the Liver (EASL)].
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis; D000328:Adult; D000367:Age Factors; D000368:Aged; D000437:Alcoholism / Q000150:complications; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D016031:Liver Transplantation; D012367:RNA, Viral / Q000032:analysis; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000150:complications; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage
D000998:Antiviral Agents; D012367:RNA, Viral; D014761:Viral Hepatitis Vaccines; D012254:Ribavirin; D007372:Interferons